REALM THERAPEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - GBX | -.--% |
|
+9.52% | +64.29% |
More press releases
| Members of the board | Title | Age | Since |
|---|---|---|---|
David Parkinson
BRD | Director/Board Member | 73 | 19-07-30 |
Tara Petta
BRD | Director/Board Member | - | - |
Realm Therapeutics plc, formerly PuriCore plc, is a biopharmaceutical company. The Company is focused on leveraging its immunomodulatory technology to protect and improve the health of adults and children. The Company has initiated drug development programs based on its hypochlorous acid technology. The Company is engaged in the development of small molecule therapies with potential application for the treatment of diseases in a number of therapeutic areas, and an initial focus in dermatology and ophthalmology. The Company has developed proprietary formulations of its technology, with anti-inflammatory and immunomodulatory benefits. Its pipeline of products include PR013 and PR022, which are in Phase I. PR013 is indicated for allergic conjunctivitis and PR022 is indicated for atopic dermatitis. Realm Therapeutics, Inc. is a subsidiary of the Company.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.82% | 41.36B | |
| +44.25% | 41.3B | |
| +2.56% | 39.61B | |
| -12.11% | 25.62B | |
| +3.09% | 24.09B | |
| -24.16% | 18.38B | |
| +22.12% | 11.85B | |
| -3.74% | 11.82B | |
| +7.75% | 11.07B |
- Stock Market
- Equities
- PURI Stock
